How to Eliminate Major Pharmacovigilance Audit Findings?
Proactive Strategies to Eliminate Pharmacovigilance Audit Findings Receiving major Pharmacovigilance Audit Findings during a US FDA or EMA inspection can lead to warning letters, financial penalties, and delays in Regulatory approvals. The key to a “zero-finding” audit is shifting from reactive fixes to a robust system of Quality management. Common Areas for Major Findings Inspectors […]